Status:
UNKNOWN
EA for PAAS: A pRCT
Lead Sponsor:
Chengdu University of Traditional Chinese Medicine
Conditions:
Substance Withdrawal Syndrome
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
In 2019, around 27 million people worldwide, corresponding to 0.5% of the adult population, have used amphetamine-type stimulants (ATS). More than one-third of these 27 million users of ATS were in Ea...
Eligibility Criteria
Inclusion
- Patients meet the diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) (21);
- A urine test for methamphetamine is negative.
- 18-60 years old, male or female, conscious, no aphasia, or mental retardation, primary school education or above, and able to understand the contents of the scales and cooperate with treatment;
- Did not participate in other clinical trials within 3 months;
- Signed the informed consent from.
Exclusion
- Local trauma or infected persons who have received EA;
- Can' not tolerate EA, EA treatment, or allergic to EA needles;
- Pregnant or breastfeeding women;
- Serious disorders of the heart, liver, or kidney, or suicidal tendencies.
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04917185
Start Date
June 1 2021
End Date
December 1 2023
Last Update
June 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Affliated Hospital of Chengdu University of Traditional Chinese Medicine
Chengdu, Sichuan, China, 610072